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Abstract
(E)-5-(2-bromovinyl)-2V-deoxyuridine (BVDU) is a potent inhibitor of herpes simplex virus type 1 (HSV-1) and varicella-zoster virus
(VZV). Its mechanism of action is based on a specific conversion to its 5V-mono- and 5V-diphosphate derivative by HSV-1- and VZV-encoded
thymidine kinase, and after further conversion to its 5V-triphosphate derivative, inhibition of the viral DNA polymerase and eventual
incorporation into the viral DNA. Recently, a new structural class of bicyclic pyrimidine nucleoside analogues (designated BCNAs) with
highly specific and selective anti-VZV activity in cell culture has been discovered. The compounds need a long alkyl or alkylaryl side-chain
at the base moiety for pronounced biological activity. This property makes these compounds highly lipophilic. They are also endowed with
fluorescent properties when exposed to light with short UV wavelength. In striking contrast to BVDU, the members of this class of
compounds are active only against VZV, but not against any other virus, including the closely related HSV-1, HSV-2 and cytomegalovirus.
The most active compounds inhibit VZV replication at subnanomolar concentrations and are not toxic at high micromolar concentrations.
The compounds lose their antiviral activity against thymidine kinase (TK)-deficient VZV strains, pointing to a pivotal role of the viral TK in
their activation (phosphorylation). Kinetic studies with purified enzymes revealed that the compounds were recognized by VZV TK as a
substrate, but not by HSV-1 TK, nor by cytosolic or mitochondrial TK. VZV TK is able to phosphorylate the test compounds not only to their
corresponding 5V-mono- but also to their 5V-diphosphate derivatives. These data may readily explain and rationalize the anti-VZV selectivity
of the BCNAs. There is no clear-cut correlation between the antiviral potency of the compounds and their affinity for VZV TK, pointing to a
different structure/activity relationship of the eventual antiviral target of these compounds. The compounds are stable in solution and, in
contrast to BVDU, not susceptible to degradation by thymidine phosphorylase. The bicyclic pyrimidine nucleoside analogues represent an
entirely new class of highly specific anti-VZV compounds that should be further pursued for clinical development. D 2002 Elsevier Science
B.V. All rights reserved.
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1. Introduction
Nucleoside analogues are well known as antiviral agents
of biological interest and clinical utility, dominating the
current treatment protocols for human viral infections. In
particular, many nucleoside analogues with interesting bio-
logical properties have arisen by substitution at the 5-
position of the uracil base in the 2V-deoxyuridine series
[1]. The 5-(2-substituted-vinyl)-2V-deoxyuridines, in partic-
ular ((E)-5-(2-bromovinyl)-2V-deoxyuridine, BVDU,
BrivudinR), have emerged as potent and selective inhibitors
of herpes virus replication, particularly against HSV-1
(herpes simplex virus type 1) [2–4]. 5-Alkynyl-2V-deoxyur-
idines have also been studied as potential antiviral agents,
the parent 5-ethynyl derivative being a potent inhibitor of
HSV-1, HSV-2 (herpes simplex virus type 2) and VV
(vaccinia virus) [4]. However, this compound is also rather
cytotoxic and its antiviral selectivity is low [4,5].
Herpes virus-encoded thymidine kinases (TK) often
appear to be able to phosphorylate 5-substituted 2V-deoxy-
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uridines to their 5V-monophosphate derivatives [6], and
HSV-1 and VZV TK can even further convert the 5V-mono-
phosphates to their 5V-diphosphate counterparts [7–9]. Most
nucleoside analogues are further phosphorylated to the
triphosphate derivatives by cellular enzymes, acting as
inhibitors of virus-encoded DNA polymerase and/or as
substrate analogues of these enzymes. Subsequent incorpo-
ration into viral DNA often represents the molecular basis of
their antiviral action, although other targets such as virus-
specified ribonucleotide reductase or even thymidylate syn-
thase [10,11] can be considered as a potential antiviral target
for the phosphorylated nucleoside analogues as well. So far,
all anti-VZV drugs and the majority of antiherpes agents are
specifically activated (phosphorylated) by the virus-encoded
thymidine kinase (TK) [2,12].
The structure of HSV-1 thymidine kinase was initially
solved as a complex with gancyclovir [13] and with the
natural substrate [14,15]. More recently, complexes of HSV-
1 TK with the antiherpes drug, acyclovir, [16] and a non-
substrate inhibitor, to high resolution, have been published
[17], but VZV TK has not been crystallized and its three-
dimensional structure is unknown. However, the numerous
detailed coordinate sets of HSV-1 TK should be of value in
determining the structure of the VZV TK, as these two
enzymes share 29% amino acid sequence identity [18].
Knowledge of the sites of binding of many ligands of
interest should provide a framework for understanding the
different substrate specificities of a range of TKs, including
those from other herpes viruses.
The chemical synthesis of 5-alkynyl-2V-deoxyuridines
involves the Pd-catalysed coupling of a terminal alkyne
with a 5-substituted (usually 5-iodo) 2V-deoxyuridine
[19,20]. Whilst these methods give reasonable yields of
the desired 5-alkynyl product, they always give variable
quantities of a fluorescent by-product, characterized as the
cyclised furano system [19–21]. Such by-products appa-
rently arise from the Pd (or Cu) catalysed cyclisation of the
desired product and, indeed, can be prepared directly from
the 5-alkynyl product upon copper treatment [19]. Previ-
ously, the only well-characterized examples of these furano
nucleosides have been the parent compound (arising from
cyclisation of 5-ethynyl-2V-deoxyuridine) [22–24] and the
n-butyl analogue [19]. Biological evaluation of these
furano nucleosides has not been extensive to date but the
parent compound was noted to be inactive against HSV-1,
HSV-2, CMV and VZV [24]. Conventional wisdom would
be that longer chain homologues would be similarly
inactive.
We have recently discovered that certain long-chain
substituted fluorescent furano bicyclic nucleoside analogues
(designated BCNAs) are in fact potent and selective inhib-
itors of VZV replication in cell culture [25–28]. This novel
discovery has great potential for further exploration with the
distinct possibility of new and improved drug discovery.
The lead compound Cf1368 has—in cell culture—an anti-
VZV activity, which is 100-fold more potent (EC50: 0.008
AM) than the current anti-VZV drug of choice (acyclovir:
prodrug Valtrex) [25]. Moreover, we could not detect pro-
nounced toxicity in cell culture. Surprisingly, this drug is
active only against VZV, being completely inactive against
any other virus, including the closely related HSV-1, HSV-2
and CMV. This pronounced antiviral selectivity is unprece-
dented.
This review describes the antiviral activities of the novel
anti-VZV compounds, their structure–antiviral activity rela-
tionships and initial studies on their metabolic/enzymatic
activation/inactivation pathways and the possible mecha-
nism of antiviral action.
2. Structure–antiviral activity relationship of BCNAs
against VZV replication in cell culture
All BCNAs were evaluated for their inhibitory activity
against VZV replication in human embryonic lung (HEL)
cell cultures. Confluent HEL cells were grown in 96-well
microtiter plates and innoculated with two wild-type (OKA
and YS) and two thymidine kinase-deficient (07/1 and YS/
R) VZV strains at 100 plaque-forming units (PFU)/well.
Antiviral activity of the test compounds was expressed as
their 50% effective concentration (EC50) or compound
concentration required to reduce viral plaque formation by
50% compared with untreated controls. The 50% cytostatic
concentration (CC50) of the BCNAs was determined as the
compound concentration required to inhibit exponentially
growing HEL cell cultures by 50% (after counting the cell
number using semiautomated Coulter counting).
2.1. BCNAs with a simple n-alkyl side-chain
Among those BCNAs that contain a simple alkyl side-
chain on the bicyclic base ring, the optimal carbon chain
length to display the most potent anti-VZV activity ranked
between 8 and 10 (Table 1). Indeed, the anti-VZV activity
(EC50) of these BCNAs was between 0.008 and 0.02 AM. At
shorter or longer side-chain lengths, the antiviral activity
markedly decreased by at least 1–2 orders of magnitude.
When compared with BVDU and acyclovir (ACV), the
most active anti-VZV BCNAs with a simple alkyl side-
chain were virtually equally effective as the antiherpes virus
drug BVDU (EC50: 0.005 AM) but at least 200-fold more
active than ACV, the current drug of choice for the clinical
treatment of VZV (Table 1). As for ACV and BVDU, the
BCNAs fully lose antiviral activity against thymidine kin-
ase-deficient VZV strains, pointing to a crucial role of the
VZV-encoded TK in the activation (phosphorylation) of the
BCNAs (Table 1). Interestingly, none of the BCNAs listed
in Table 1 were toxic to HEL cell proliferation at concen-
trations as high as 50–200 AM. As a result, the selectivity
index (ratio CC50/EC50) of the prototype compounds
Cf1368, Cf1369 and Cf1676 is at least as high as 5000–
20,000.
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2.2. BCNAs with terminal alkyl unsaturation
A variety of BCNAs were synthesized containing a
terminal alkyl unsaturation in the side-chain on the furanyl
ring of the bicyclic base (Table 2). Although a significant
antiviral activity was recorded for the N-alkenyl- and N-
alkynyl-BCNA derivatives, there is clearly a decreased
antiviral efficiency of the N-alkenyl-, and even more of the
N-alkynyl-BCNAs. Compared with the n-octyl-BCNA
derivative (Cf1368), the N-octenyl-BCNAs lost f 10-fold
antiviral activity, and the N-octynyl-BCNAs lost approxi-
mately 300-fold anti-VZVactivity relative to the correspond-
ing parental n-octyl-BCNA (Table 2). As found for the
simple n-alkyl-substituted BCNAs, the terminally unsatu-
rated n-alkenyl- and n-alkynyl-BCNAs completely lost anti-
viral activity against VZV TK strains (data not shown).
2.3. BCNAs with a terminal halogen substitution in the n-
alkyl side-chain
When the terminal methyl group of the alkyl side-chain
of the n-decyl-BCNA was replaced by a halogen, N-fluoro
substitution virtually retained full antiviral efficacy, and the
N-chloro-, N-bromo- and N-iodoalkyl-substituted BCNAs
marginally lost antiviral efficacy (up to 2–4-fold) (Table 3).
There was no significant difference for the anti-VZV activ-
ities of the different N-halo-substituted alkyl-BCNAs.
2.4. BCNAs with an n-alkylaryl side-chain
In an attempt to restrict the conformational freedom of
the alkyl side-chain of the prototype BCNAs Cf1368 and
Cf1369, an aromatic ring system (phenyl) was introduced in
the side-chain. In particular, a variety of p-alkylphenyl-
BCNAs have been synthesized and evaluated for anti-
VZV activity. As is clear from the antiviral data depicted
in Table 4, several members of the alkylaryl-BCNAs were
exquisitely inhibitory against VZV replication. In particular,
the n-pentylphenyl- and n-hexylphenyl-BCNAs were anti-
virally active at a concentration as low as 0.0001–0.0005
AM, being endowed with a 10–50-fold higher antiviral
potency than the original prototype alkyl-BCNAs Cf1368
and Cf1369. Interestingly, longer and shorter alkyl groups at
the para position on the phenyl group of the BCNAs led to
lower antiviral activities (Table 4). In fact, shortening or
lengthening the optimal pentylphenyl by only two to three
carbons lead to a more than 100-fold lowering of the
antiviral activity of the test compounds. The existence of
an optimal chain length and the close dependence of the
anti-VZV activity on the alkylaryl chain length have been
also observed for the simple n-alkyl-substituted BCNAs.
There appeared a strong correlation between the size
Table 2
Anti-VZVactivity of BCNAs containing a terminal alkyl unsaturation in the
side-chain of the furanyl ring
Compound Side-chain R EC50 (AM) (VZV)a CC50 (AM)a
OKA YS
Cf1382 (CH2)4CH2UCH3 1.3 2.8 >200
Cf1657 (CH2)4CHMCH2 14 13 >200
Cf1625 (CH2)4CQCH 25 33 >200
Cf1368 (CH2)6CH2UCH3 0.008 0.02 >50
Cf1658 (CH2)6CHMCH2 0.27 0.06 >200
Cf1662 (CH2)6CQCH 5.0 4.0 >200
a Data from Ref. [29].
Table 1
Anti-VZV activity of BCNAs containing an alkyl side-chain of the furanyl
ring
Compound Total carbons in EC50 (AM)a CC50 (AM)a
alkyl side-chain
VZV VZV TK
OKA YS 07 YS-R
Cf1382 6 (hexyl) 1.3 2.8 > 50 >50 >200
Cf1398 7 (heptyl) 0.12 0.33 >50 >50 >50
Cf1368 8 (octyl) 0.008 0.02 >50 >50 >50
Cf1676 9 (nonyl) 0.02 0.02 >200 >200 >200
Cf1369 10 (decyl) 0.02 0.008 >50 >50 >50
Cf1717 11 (undecyl) 0.4 0.37 >50 >50 >200
Cf1449 12 (dodecyl) 0.8 1.2 >50 >50 >200
BVDU – 0.005 0.005 >50 >50 >400
ACV – 1.9 2.1 >50 >50 >200
a Data from Ref. [25].
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(length) of the n-alkyl and n-alkylaryl moiety of the BCNAs
on the one hand, and their optimal antiviral activity on the
other (Fig. 1). In fact, if the size of the phenyl group in the
alkylaryl-BCNAs is considered as equivalent to f 4 meth-
ylene groups, the butylaryl-, pentylaryl- and hexylaryl-
BCNAs and the octyl-, nonyl- and decyl-BCNAs represent
members within each series of BCNAs with the highest
antiviral potency (Tables 1 and 4; Fig. 1). It is striking,
however, that the alkylaryl-BCNAs are invariably more
potent than the n-alkyl-BCNAs. This may likely be related
to the reduced conformational freedom of the alkylaryl side-
chain relative to the long alkyl side-chain and, therefore, the
alkylaryl-BCNAs may more optimally fit to their target
enzyme than the more flexible n-alkyl-BCNAs. The pentyl-
phenyl-BCNA represents the most potent anti-VZV com-
pound hitherto reported. Due to lack of measurable cellular
toxicity at 200 AM, its antiviral selectivity (ratio of CC50/
EC50) amounts to f 1,000,000, and its anti-VZV potency is
10–30-fold more pronounced than BVDU, and f 10,000-
fold more pronounced than ACV.
2.5. BCNAs with other heteroatoms in the bicyclic ring
The parent furano nucleus in the BCNAs has also been
changed to a pyrro or thieno ring system, and the antiviral
activities of these analogues compared for a series of n-
alkyl-substituted BCNAs (Table 5). Whereas substitution
of the oxygen in the furano moiety by a nitrogen ge-
nerally reduced the antiviral activity by 10–50-fold, the
replacement of the oxygen by a sulfur atom resulted in
most cases in a further 5–10-fold increased anti-VZV
activity. It is unclear whether the increased potency of
Table 3
Anti-VZV activity of BCNAs containing a terminal halogen substitution in
the alkyl side-chain of the furanyl ring
Compound R EC50 (AM) (VZV)a CC50 (AM)a
OKA YS
Cf1656 F 0.022 0.014 200
Cf1770 Cl 0.04 0.02 200
Cf1558 Br 0.03 0.03 >50
Cf1649 I 0.06 0.03 >200
Cf1369 CH3 0.02 0.008 >50
a Data from Ref. [30].
Table 4
Anti-VZVactivity of BCNAs containing a p-alkyl-substituted phenyl group
as the side-chain of the furanyl ring
Compound R EC50 (AM) (VZV)a CC50 (AM)a
OKA YS
Cf1837 H 0.28 0.16 >200
Cf1835 Methyl 0.06 0.06 >200
Cf1836 Ethyl 0.09 0.07 123
Cf1698 n-Propyl 0.01 0.008 188
Cf1744 n-Butyl 0.002 0.0005 >200
Cf1743 n-Pentyl 0.0003 0.0001 >200
Cf1742 n-Hexyl 0.0005 0.0001 18
Cf1712 n-Heptyl 0.005 0.003 18
Cf1711 n-Octyl 0.04 0.03 >200
a Data from Ref. [26].
Fig. 1. Correlation between the anti-VZVactivity of the simple n-alkyl- (E)
(alkyl chain length R-1) and alkylphenyl-BCNAs (.) (alkyl chain length
R-2) and the carbon side-chain length of the molecules. Assuming that the
phenyl group in the alkylaryl-BCNA series accounts for four-carbon chain
lengths, the correlation of optimal anti-VZV activity between both series of
compounds fits very well.
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most thieno-BCNAs compared with the furano-BCNA is
of benefit due to the higher cellular toxicity of the thieno-
BCNAs.
2.6. BCNAs with a different sugar moiety
Since the arabinosyl derivative of BVDU (designated
BVaraU or SorivudineR) is at least as potent an antiherpetic
agent as the deoxyriboside derivative [33], and since it has
also been reported that BVriboU is endowed with antiher-
petic activity [34], the sugar-modified arabinosyl and ribo-
furanosyl derivatives of the prototype n-octyl-BCNA
(Cf1368) were synthesized and evaluated for their antiviral
(VZV) potencies (Table 6). In marked contrast with
BVaraU, the arabinosyl-BCNA was 300-fold less potent
as an anti-VZV agent than its 2V-deoxy derivative, and the
BCNA riboside was 3000-fold less potent in its anti-VZV
activity. The free n-octyl-bicyclic base was devoid of any
measurable anti-VZV activity (as also observed for BVU,
the free base of BVDU).
3. Lipophilicity and water solubility of BCNAs
There is a stringent requirement of a relatively long alkyl
or alkylphenyl side-chain at C-6 of the bicyclic furano or
thieno pyrimidine ring of the BCNAs to display optimal
anti-VZV activity. This property results in a relatively high
lipophilicity of the compounds (represented by their calcu-
lated log P values (ClogP) that range between 2.5 and 3.5).
This striking observation has been noticed for the different
series of BCNAs, including the n-alkylfurano (series 1),
alkylphenylfurano (series 2), terminally unsaturated n-alkyl-
furano (series 3), n-alkylthieno (series 4) and n-alkylpyrro
(series 5) BCNAs (Fig. 2). The fact that a higher lip-
ophilicity of BCNAs more or less corresponds with higher
bulkiness of the side-chain, it is conceivable that an optimal
ClogP value for optimal anti-VZVactivity reflects an optimal
lipophilic interaction in the active site of the enzymes, or an
optimal size of the side-chain that must fit in a lipophilic
pocket of the particular enzymes. In an attempt to enhance
the water solubility of the lead BCNAs, replacement of one
of the methylene units in the n-decyl-BCNA chain by an
oxygen (resulting in glycol/ether derivatives of the n-decyl-
BCNA) resulted in a dramatically decreased ClogP value of
f 1.1 and a concomittantly decreased antiviral activity by
100- to >1000-fold [35]. Also, the terminally unsaturated n-
alkyl-BCNAs have a low (alkene) to dramatically lower
(alkyne) ClogP, and also a concomittant 50–500-fold lower
antiviral activity [29]. However, in both glycol/ether and
terminal unsaturated n-alkyl-BCNA series, the overall size
of the side-chain is virtually constant. Therefore, these
observations suggest that the overall lipophilicity, rather
than the size of the side-chain, is a predominant property
Table 5
Anti-VZV activity of BCNAs containing different hetero atoms in the five-
membered ring of the base
Compound Nature Carbon EC50 (AM) (VZV)a CC50 (AM)a
of the X
hetero atom
length in
n-alkyl (R)
side-chain
OKA YS
Cf1382 O 6 1.3 2.8 >200
Cf1368 O 8 0.008 0.02 >50
Cf1369 O 10 0.02 0.008 >50
Cf1449 O 12 0.8 1.2 >200
Cf2011 S 6 0.08 0.08 >200
Cf2012 S 8 0.001 0.001 53
Cf1603 S 10 0.03 0.06 54
Cf2013 S 12 0.20 0.20 49
Cf1395 NH 6 >50 >50 >50
Cf1397 NH 8 0.15 0.48 >50
Cf1681 NH 10 f 10b f 2b >200
Cf1450 NH 12 2.4 14 >200
a Data from Refs. [25,31,32].
b An accurate EC50 value could not be calculated due to incomplete
inhibition of VZV replication at higher drug concentrations and lack of a
consistent dose– response curve.
Table 6
Anti-VZV activity of BCNAs as a free base, or with modifications in the
sugar moiety
Compound Sugar configuration EC50 (AM) (VZV)a CC50 (AM)a
OKA YS
Cf1368 2V-deoxyribose 0.008 0.024 >50
Cf1400 ribose 23 21 50
Cf1433 arabinose 3.6 3.3 >20
Cf1381b – >20 >20 >20
Cf2200c – >20 >20 >20
a Data from Refs. [27,28].
b Free base of Cf1368.
c Free base of Cf1743.
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that eventually determines the antiviral potency of the test
compounds. It may be somewhat surprising that a presumed
lipophilic pocket to accommodate the rather bulky side-
chain on the bicyclic pyrimidine ring of the BCNAs must be
able to optimally adapt in at least two different enzymes (the
activating (phosphorylating) VZV TK and the eventual anti-
viral target enzyme).
Although the high lipophilicity of the BCNAs results in a
low to very low water solubility ( < 1 mg/l of the n-decyl-
BCNA at room temperature), it is expected to lead to an
efficient penetration of the BCNAs through cellular mem-
branes and biological barriers such as the blood/brain barrier
and the skin. This property may be advantageous for this
novel class of anti-VZV compounds because uptake of the
lipophilic BCNAs into cells and into biological compart-
ments that may harvest the virus, may be facilitated by the
higher lipophilicity of these drugs.
4. Anabolic conversion of BCNAs to their
phosphorylated derivatives
Since the BCNAs listed in Tables 1–6 markedly lose
antiviral activity against VZV strains that are deficient in the
virus-encoded thymidine kinase, it can be anticipated that
the compounds need to be activated (phosphorylated) by the
viral TK before they inhibit their antiviral targets.
A variety of BCNAs, in particular the series of n-
alkylphenyl-BCNAs, were evaluated for their inhibitory
effect against 1 AM [3H]dThd phosphorylation by VZV
TK, HSV-1 TK, HSV-2 TK, TK-1 and TK-2 (Table 7). Only
VZV TK-catalysed [3H]dThd phosphorylation was inhibited
by the BCNAs, reflecting their affinity for VZV TK, likely a
competitive inhibition of the enzyme reaction with the
natural substrate. It also became obvious from these data
that there was no close correlation between affinity for VZV
TK and the eventual anti-VZVactivity of the BCNAs. These
observations make it clear that the SARs of the activating
(phosphorylating) enzyme are different from those of the
(antiviral) target enzyme.
Cf1368 and Cf1369 were directly investigated as sub-
strates for purified VZV TK, and also for purified HSV-1
and HSV-2 TK [36]. Interestingly, only VZV TK measur-
ably converted the compounds to their 5V-monophosphate
derivatives. By contrast, BVDU was easily converted to its
5V-monophosphate derivative by VZV TK, and also by
HSV-1 TK, and HSV-2 TK (and mitochondrial TK) [6].
BVDU is not measurably phosphorylated by cytosolic TK-
Fig. 2. Correlation between calculated logP (ClogP) of BCNAs and their
anti-VZVactivity. The data of five series of BCNAs are shown. Series 1: n-
alkyl-BCNAs (Table 1). Series 2: n-alkylphenyl-BCNAs (Table 4). Series 3:
terminal unsaturated n-alkyl-BCNAs (Table 2). Series 4: thienopyrimidine
BCNAs (Table 5). Series 5: pyrrolopyrimidine BCNAs (Table 5).
Table 7
Inhibitory effect of n-alkylphenyl-BCNAs against [3H]dThd phosphoryla-
tion by cytosolic TK-1, mitochondrial TK-2, HSV-1 TK, HSV-2 TK and
VZV TK
Compound R IC50 (AM)a
TK-1 TK-2 HSV-1 TK HSV-2 TK VZV TK
Cf1837 H >500 >500 z500 0.37
Cf1835 Methyl >500 >500 >500 3.1
Cf1836 Ethyl >500 >500 >500 >500 13
Cf1698 Propyl >500 >500 >500 >500 25
Cf1744 Butyl >500 >500 >500 >500 4.7
Cf1743 Pentyl >500 >500 >500 >500 3.9
Cf1742 Hexyl >500 >500 >500 >500 4.5
Cf1712 Heptyl >500 >500 >500 3540
Cf1711 Octyl >500 >500 >500 >5000
Cf1368 >500 >500 >5000 >5000 37
BVDU >1000 0.34 2.9 5.6 1.5
a 50% Inhibitory concentration or compound concentration required to
inhibit nucleoside kinase-catalysed phosphorylation of 1 AM [CH3-3H]dThd
by 50%.
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1. Compared with BVDU, the BCNAs had a much higher
Vmax but also a much higher Km, for VZV TK. The exact
Vmax values for the BCNAs could not be measured due to
limited solubility of the compounds, in the millimolar con-
centration range.
We also evaluated the 5V-monophosphate derivatives of
Cf1368 (Cf1928) and Cf1369 (Cf1602) as substrates for the
dTMP kinase activity associated with VZV TK and HSV-1
TK [36]. Again, both enzymes displayed a striking discrim-
ination between BVDU-MP and the BCNA-MPs. Whereas
BVDU-MP was efficiently converted by both enzymes to its
5V-diphosphate derivative (BVDU-DP), only VZV TK, but
not HSV-1 TK, was able to recognize the BCNA-MPs as
efficient substrates for phosphorylation. Cellular dTMP
kinase was also unable to recognise the BCNA-monophos-
phates. Thus, it became clear that the BCNAs are selectively
phosphorylated to their 5V-diphosphates by the two succes-
sive enzyme activities of VZV TK (thymidine kinase and
dTMP kinase), while they are not recognized by the TK/
dTMP kinase activity of HSV-1 or the cytosol under similar
experimental conditions (Fig. 3a). In this respect, the
BCNAs strikingly differ from BVDU (Fig. 3b) and our
observations provide an explanation for the unprecedented
inhibitory specificity of the BCNAs for VZV.
Interestingly, when human erythrocyte NDP kinase was
added to a reaction mixture containing BVDU or BCNAs
and VZV TK, a considerable amount of BVDU-TP was
formed, whereas no trace of BCNA-TP could be detected
[36]. Although it cannot be excluded that the BCNA-DPs
can be recognized by other NDP kinase isoenzymes or by
other (less obvious) cellular enzymes, our observations may
indicate that the mechanism of anti-VZV activity of the
novel class of BCNAs may be entirely different from that of
BVDU (being a competitive inhibitor of viral DNA poly-
merase and incorporated into viral DNA upon conversion to
the 5V-triphosphate derivative). This is being further studied
in our laboratories.
5. Catabolic conversion of BCNAs by cellular enzymes
Nucleoside analogues may be prone to catabolic hydrol-
ysis by several enzymes (i.e., purine nucleoside phosphor-
ylase (PNPase), thymidine phosphorylase (TPase), uridine
phosphorylase (UPase)). In particular, 2V-deoxyribonucleo-
side analogues such as BVDU are good substrates for
thymidine phosphorylase, which efficiently converts BVDU
to its free (antivirally inactive) base BVU [37]. Crystals of
E. coli TPase complexed with the natural substrate dThd
[38] demonstrate that the hydrogen at the N(3) position of
the pyrimidine ring forms a hydrogen bridge with amino
acid Ser-186 of TPase, and the carbonyl group at position 4
of the pyrimidine ring forms a close interaction with amino
acid Arg-171. Interestingly, the BCNAs have no free car-
bonyl at the same position in the pyrimidine ring, but more
importantly, due to the fused ring system, the bicyclic base
Fig. 3. (a) Metabolic fate of BCNAs. BCNA is converted to its 5V-mono-
(BCNA-MP) and 5V-diphosphate (BCNA-DP) by TK encoded by VZV, but
not by HSV-1 TK, HSV-2 T, mitochondrial TK-2 or cytosolic TK-1.
BCNA-DP is not a substrate for E. coli or human erythrocyte nucleoside
diphosphate kinase (NDP-K). It is not known whether other cellular
enzymes may recognize BCNA-DP as a substrate to be converted to
BCNA-TP. BCNA is not measurably hydrolysed by E. coli or human
erythrocyte TPase to its free base [39]. The free bicyclic base does not
inhibit dihydropyrimidine dehydrogenase (DPD) [39]. (b) Metabolic fate of
BVDU. BVDU is converted to its 5V-monophosphate derivative by the TKs
encoded by HSV-1, HSV-2 and VZV, and by mitochondrial TK-2, but not
by cytosolic TK-1. BVDU-MP inhibits thymidylate synthase (TS). BVDU-
MP is converted to its 5V-diphosphate derivative by the TKs encoded by
HSV-1 and VZV TK, but not by HSV-2 TK or cytosolic dTMP kinase
(dTMP-K). BVDU-DP is converted by NDP kinase (NDP-K) to BVDU-TP.
The latter metabolite is recognized by cellular and herpetic DNA
polymerases, and incorporated into viral and cellular DNA. BVDU is
hydrolysed by thymidine phosphorylase (TPase) to its free base BVU,
which in turn is a potent inhibitor of dihydropyrimidine dehydrogenase
(DPD).
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of the BCNAs has no hydrogen available on the original
N(3) position of the pyrimidine ring. Therefore, it could be
anticipated that TPase would not efficiently recognize the
BCNAs as substrates for cleavage to the free base. Indeed,
when the BCNAs were exposed to both E. coli or human
TPase, no hydrolysis to the free base could be detected
under conditions where BVDU and dThd were markedly
converted to their free bases BVU and Thy, respectively
[39]. It follows that—in contrast to BVDU—the BCNAs do
not act as substrates for the catabolic TPase and thus, should
be rather stable in biological systems (i.e., plasma). Indeed,
preliminary experiments in which Cf1368 was administered
both intravenously or perorally, no indication of release of
the free base was obtained, and a pronounced appearance of
unaltered drug in plasma upon oral administration was
found (unpublished data).
6. Conclusions
The novel class of BCNAs represents the most potent
and selective anti-VZV compounds hitherto described. The
selectivity is at least partially based on a specific ability of
VZV TK to convert the compounds to their 5V-mono- and 5V-
diphosphate derivatives. Although the BCNAs have a num-
ber of interesting properties that make them prime candi-
dates for further development to the clinic, their molecular
mechanism of action remains to be resolved and is currently
the subject of further investigations.
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